5

	Application Number		10790901	
	Filing Date		2004-03-01	
INFORMATION DISCLOSURE	First Named Inventor Jeffre		frey C. Smith	
STATEMENT BY APPLICANT ( Not for submission under 37 CFR 1.99)	Art Unit		2439	
(NOTION SUBMISSION WHILE ST OF R 1.33)	Examiner Name Karı L		L. Schmidt	
	Attorney Docket Numb	er	127-0007-2	

U.S.PATENTS Remove							
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	
	1	5671412		1997-09-23	Christiano		
	2	6591263	B1	2003-07-08	Becker et al.		
	3	6571290	B2	2003-05-27	Seigas et al.		
	4	6567914	B1	2003-05-20	Just et al.		
	5	6560644	B1	2003-05-06	Lautmann et al.		
	6	6321267	B1	2001-11-20	Donaldson		
	7	6304898	B1	2001-10-16	Shigi		
	8	6285777	B2	2001-09-04	Kanevsky et al.		

9	6275575	B1	2001-08-14	Wu	
10	6240088	B1	2001-03-29	Gayton et al.	
11	6219694	B1	2001-04-17	Lazaridis et al.	
12	6199103	B1	2001-03-06	Sakaguchi et al.	
13	6199102	B1	2001-03-06	Cobb	
14	6185551	B1	2001-02-06	Birrell et al.	
15	6157630		2000-12-05	Adier et al.	
16	6131120		2000-10-10	Reid	
17	6073165		2000-06-06	Narasimhan et al.	
18	6073142		2000-06-06	Geiger et al.	
19	6040784		2000-03-21	Miller	

	Application Number		10790901	
	Filing Date		2004-03-01	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	First Named Inventor Jeffre		ey C. Smith	
(Not for submission under 37 CFR 1.99)	Art Unit		2439	
( Not for Sabilission ander or or it 1.50)	Examiner Name	Kan L	Schmidt	
	Attorney Docket Numb	er	127-0007-2	

20	6021427		2000-02-01	Spagna et al.	
21	5999932		1999-12-07	Paul	
22	5995597		1999-11-30	Woltz et al.	
23	5978837		1999-11-02	Foladare et al.	
24	5493692		1996-02-20	Theimer et al.	
25	6263064	B1	2001-07-17	O'Neal et al.	
26	6360254	В1	2002-03-19	Linden et al.	
27	6363140	B1	2002-03-26	Pinard	
28	6421709	B1	2002-07-16	McConnick et al.	
29	6424828	B1	2002-07-23	Collins et al.	
30	6532489	B1	2003-03-11	Merchant	

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99) At Unit Examiner Nar Attornev Dock

B1 2002-09-03

31 6446118

32 6067561

	Filing Date First Named Inventor Jeffrey Art Unit Examiner Name Karl L		10790901		
			2004-03-01		
			y C. Smith		
			2439		
			Schmidt		
			127-0007-2		

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
			U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
If you wis	h to add	additional U.S. Pater	nt citatio	n information pl	ease click the Add button.	Add
	39	6438215	B1	2002-08-20	Skladman et al.	
	38	6609106	B1	2003-08-19	Robertson	
	37	6601102	B2	2003-07-29	Eldridge et al.	
	36	5963915		1999-10-05	Kirsch	
	35	6606647	B2	2003-08-12	Shah et al.	
	34	6463462	B1	2002-10-08	Smith et al.	
	33	6282565	B1	2001-08-28	Shaw et al.	
	32	6067561		2000-05-23	Dillon	

Gottlieb

2000.05-23 Dillon

	1							
If you wish to add additional U.S. Published Application citation information please click the Add button. Add								

FOREIGN PATENT DOCUMENTS Remove								
Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T4
	1	9965256	wo		1999-12-16	Fernandez et al.		
	2	9963709	wo		1999-12-09	Mousseau ot al.		
	3	9917241	wo		1999-04-08	Moon et al.		
	4	0041366	wo		2000-07-13	Conner		
	5	0833492	EP	A2	1996-09-27	Foladare et al.		
	6	19832433	DE	A1	1999-02-04	Pinards		
	7	0008793	wo		2000-02-17	Senator et al.		
	8	9906929	wo		1999-02-11	Hall		П

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10790901		
Filing Date		2004-03-01		
First Named Inventor	Jeffre	y C. Smith		
Art Unit		2439		
Examiner Name	Kan L	. Schmidt		
Attorney Docket Numb	er	127-0007-2		

			NON-PATENT LITERATURE DOCUMENT	s	Remove	_		
Examiner Initials*	Cite No	(boo	de name of the author (in CAPITAL LETTERS), title of the article k, magazine, journal, serial, symposium, catalog, etc), date, page sher, city and/or country where published.			Тs		
	1 Paime et al. "Issues when designing filters in messaging systems." Computer Communications, Elsevier Science Publishers BV: Amsterdam, NL. vol. 19, no. 2. February 1, 1996, Pages 95-101.							
If you wis	h to a	dd add	ditional non-patent literature document citation information please	e click the Add b	outton Add			
			EXAMINER SIGNATURE					
Examiner Signature Date Considered								
			reference considered, whether or not citation is in conformance rmance and not considered. Include copy of this form with next of					

See Kind Codes of USPTO Patent Documents at invent (ISPTO, GDI/c or MPEP 901.04. 2 Enter office that issued the document, by the Involved (WIPO) Standard ST3.) 3 For Lapraence patent document, the ordication of the parent of the register or precised the serial review for the patent document. If American ordinary is appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 2 Applicant is to place a check mark here if Empirical requirements on its attached.

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10790901		
Filing Date		2004-03-01		
First Named Inventor	Jeffre	y C. Smith		
Art Unit		2439		
Examiner Name Kari L		Schmidt		
Attorney Docket Numb	or	127-0007-2		

#### CERTIFICATION STATEMENT

Please see 37	CFR 1.97 ar	d 1.98 to make the	appropriate selection(s):
---------------	-------------	--------------------	---------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.37(e)(1).

#### OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 157(4)(c)

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.
- ▼ None

#### SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/David W. OBrien/	Date (YYYY-MM-DD)	2012-02-16
Name/Print	David W. OBrien	Registration Number	40107

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete his form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1449, Alexandriv, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandriva, V.S. 2311-1450.

#### Privacy Act Statement

The Privacy Act of 1974 (P. L. 95.79) requires that you be given certain information in connection with your submission of the attached form reliable to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) famishing of the information solicide to inculturally, and (3) the principal purpuse for which the information is used by the U.S. Patient and Trademan Kolline is to process and/or oxomine your submission related to a patient application or patient. If you do not furnish the requested process and/or oxomine your submission related to a patient application or patient. If you do not furnish the requested required to the process of the private of the process of the private of the process of the process

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record perfains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, oursuant to 5 U.S.C. 552a(m.).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designee, during an inspection of records conducted by GSAs a part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2504 and 2506. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 12(b) or issuence of a plentin pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the inflations of 37 GPR 1.14, as a routine use, to the public if the record vas filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, one an opulie inspections or an issued patient.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.